Singular Genomics Systems (OMIC) 3 Mar 222021 Q4 Earnings call transcript

Good day, and thank you for standing by. Welcome to the Singular Genomics Fourth Quarter Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] I would now like to hand the conference over to your host today, Philip Taylor. Please go ahead.

operator. you, Thank Singular Spaventa; are and Executive Chief Presenting Head Genomics of Drew and Finance, Officer, today Founder Dalen Meeter. Genomics year XXXX. Earlier months Singular released for results today, the and full ended XX, December financial three company's A copy release press of website. on is available the the

Before information. as implied Securities Actual to you earlier issued and predictions, of in will X, certain Exchange and uncertainties. only results and expressed would may today, described differ that today's call materially include like questions the release risks and other as expectations, risks and and today plans, including Commission. to from those March estimates, your and These uncertainties or during fully press of I are opinion forward-looking reflect in more a we comments begin, inform our responses management's statements, result statements views our with and filings XXXX,

our Investors note undue on forward-looking update SEC found or any obligation Please these the filings or place to this website not to revise website. on forward-looking SEC's reliance We cautioned disclaim statements. be can that statements. Our on are News I will Events Investors over audio be available the our on Spaventa. on at section to on will that, turn call Drew the the page page. CEO, of replay With singulargenomics.com our Events conference website for & call

latest differentiated to additional into commercial updates in a provide our the XXXX Thank and we customer's deliver deeper value everyone an us. as GX our front benefits on are its and product few business cost Singular progress I'm commercial GX the needs, call. our early conference roadmap results some our production significant quarter customer will positioned to from near tap of the you, touch we progress excited how prepared welcome system shipments. our program and on GX fourth key remarks on and accomplishments, serve and Philip, first Genomics launch. update proposition, the I'll color access opportunity of share recent to and areas; My

provide pricing I'll detail on value. and more Lastly,

In its addition high sciences first we frontier goal in of raised a will the core and GX and multiomics level instrument diagnostic tools the the biological to medicine billion customers' $XX tenants delivering NGS. progress, life advancements space on markets public benchtop by The Biological with the pricing precision time. flexibility has market inherent as our proposition is cycle is standard capital next discovery. the Genomics of emerging for record to experienced most over value active on to and adoption further of increased lower and costs opportunities of NGS XXXX, With Clinical multiomics the and technologies, medical in are throughput of tools, front in driving research, of record biological we powered speed, substantiating discovery investment power, XXXX this, sequencing and and utilization our creation accuracy, company share in between is based us. NGS largely ramping. large as continue of adoption care strong seeing a by

opportunity the discovery and to are enable in Singular at Here seizing this Genomics, ecosystem. we accelerate

develop, and genomics a work clinical multiomics. and transformative life that strong manufacture empower to research tools are in We sciences position in and will commercialize

are confident our position near to and success. continue We and execute roadmap timelines and both on we long-term for in our

flexibility, XXX supporting XXX, and XXX to orders system. speed, announced flow GX the sets on remain have kits. taken commercial track launch XXXX, system FX December sequencer benchtop GX the along the the with production product, initial customer first a cycle ship the we second we accuracy GX and in are that announce of benchmark quarter In cells and first we cost. new happy Our in Today power, to of

higher hours, for cell sequencer. XX establishing X.X billion on in world's powerful launch running to produce of remain itself throughput applications. billion flow in X.X most to data to parallel, reads FX also flow up less can single FX the a approximately as fourth four GX than benchtop track the With and We XXXX XXX the in cells of quarter Gigabase

As we purpose-built customer the previously, direct have was meet outlined based the needs. on to field GX from feedback

improved the of year all one, metrics, Over times. past we the performance run have key four number faster including,

commercial minute cycle currently are We Number two, achieving X.X target. times, our accuracy.

accuracy are and end or number of QXX XX% range of XX% to and our target at reads. single XX.X% accuracy to the published on XX.X% above scores above Number base We high for achieving of three, -- of calls. pass

our above flow read paired for million counts reads XXX four, We read are target lengths. specs FX of achieving Number cells.

reported in The systems sequencing are their capabilities, of GX where accuracy XXX these conference novel we validated runs. access achieving range To in wide a initiated labs. partners optimize program has base results EIP, transcriptomics, we Biotechnologies Q-score previously first our now above read the EIP our paired identities our Sciences. and demonstrate and sites, we QXX. last two reads and sites, biopsy, for from Site Beth Adaptive or settings and EIP Israel and and to the Exact are and We early flow labs partner per running targets three, three of as as call, applications. technology Deaconess On our reporting lab sequencing customer pleased cell such one greater to was XX% Medical than results Harvard's of Today, or revealed applications bases up targeted including at spatial Center. of liquid share million XXX ran

group. our from members orders forward to initial Exact as We received look customer have delivering and early these Adaptive and for key value partners both of access

program elected a We have in hope we the the take that what are caliber to this growing support will of next of the pleased beneficial mutually be step companies relationship. the and and with early

Site and of genome core greater than provide sequencing or achieved bases we CRO XX% kits. today liquid microbial a five. accuracy, XX% cycle than addition, perform read an million recounts above EIP recounts sequencing. commercial four XXX million QXX at performed update cell, XXX flow of and XXX Site on five, QXX In achieved XXX than using are XXX cycle flow of four, per base They cell, at bases sites greater using government greater of excited lab per biopsy sequencing to or above kits. a average average two by on accuracy, paired

provides We and across and between to that of broad have foundation we early specifications the for necessary some our over lab installed are additional validating In beta execution of commercialization. summary, our at two labs. settings EIP successful achieved the year validated applications pleased The programs target GX instruments access have early further performance specs sequencing sites, and target and represent seven partner these independent our customers program, markets. at test performance these the last various

like we whole and demonstrate update, sequencing genome and high in In sequencing the addition shared with to yet intended system has in confidence report our common art us. and to published of genome data report to This GX applications, production improve. regions the performance technical evaluated XXx, with sharing the GX anticipate for interest the highlight was the additional milestone as a reference with single most We quality. information at of our XX.X% we discussions This It approximately performance and accuracy facilitate important industry. target many is The information of our to The commercial connection one coverage. system would report with technical continue contained data comprehensive coverage on for par the produced our and XXx, and customers human transparent sequencing. of performance launch. related the to XXx uniform pass performance stimulated an across of state in overview current

associated value The seamlessly customer's these a of our specifications, cost a plug are power, performance the there workflow integration. to and of addition I'll advantages speed proposition tenants system's of are GX Each potential the new into resonating are workflows. We provides operational In flexibility now. technology. These areas. each the sequencing these include with other and existing considerations proposition in outstanding customer talk core direct in of develop about that of value to of the GX Workflow aspects savings. customers. GX integration, these each compelling with evaluation

validating and As With HyperPrep Agilent, enrichment validating library England in its are products we prep QIAseq kits, for are DNA are Watchmaker library we are highly and we we sure product new both Lexogen, Dovetail entered to library with providers BioLabs, its its Bioscience, prep all Across a market-leading Operational three powerful data These hours. ability for announced have Institute Qiagen, solution announce Board The giga New and GX such line Twist Roche, for both With less XXX to billion the the The excited with or these and GX any X.X reduce on a we day data advantages. optimize partnership our solutions the the single integrate run as platform. the partners, nine billion to seamlessly Tara is informatics the more well market. up XX per with to sequencer will customers benchtop as benchtop provide custom the Genomics and validating Roche, EvoPlus X.X kits. other target of select KAPA catalog the Genomics compatibility performance basis with are sensitive Qiagen. GX partnerships sequencer, to previously prep than partnerships and most than prep. With in kits. plan we sample addition that its into GX. and integrate approximately Agilent, reads these RNA to with to

upon the already lower more cost in to range. four by experiment and sequencing cells These that differentiated flexibility that run allows form list savings, customer take this sample proposition addressable unparalleled translates individually optimize need and combination forms; advantages to cost more and results. to direct discounting. offers per we volume Direct price I savings capacity, further GX or and faster flow build the savings. customers highly cost of scale. related additional especially speed direct mentioned The customers value for The to a proposition. the addition, with of feel cost two and high flow volume Yet flexibility established value offering This In just efficiently intend frequently. cells savings run operational

in per pricing to a comparable GX, basis read dollars offerings. First versus kit or we on savings per the the plan that kit on dollars offer base existing giga based results

volume, the up to providing the benchtop scale Second, offerings. segment. effective customer with within low more high GX, over see for to their and or mid cost significant some offer discounting, savings we plan to sequencing benchtop volume customers a current cases, way in XX% based types, will All cost

is a will share by about offer The GX customers. upcoming for benchtop a GX are The four with the compute data on a turnaround first four benchtop instrument GX by access system. cost GX will at customer and and cost. integrated by rapid giga times of GX high flexibility, providing and per also volume solution level We four to higher four random capabilities, four excited significant power, cost-efficient The single $XX speed, information savings the on by sub configuration of with base some scalable, storage, intended instruments pricing the offer at for an combination near time accuracy throughput scale. unmatched

the and benchtop sequencing their With to to and customers applications as market the cost a benchtop segment. effective needs GX which the This as four, meet needs in GX system redefine has and Singular potential choices current a are scale. by the their suitable offer they expand

are hiring support customer commercial early with sales and We scaling engage actively to our our personnel team, customers. and service support and

such team are sales, to In customer people customer and commercial end head We marketing count lab offer via and connection the streamline help This system in testing. will and interested a service are new customer data optimization who service and with applications expect ramp a to technology. new year. of validate their prospective we will support an to an by our to seeing and HD-seq be also internal specialized work customers prior to XR-seq. simple kits to care on the adoption as serve up the courtesy opportunity a XX of our setting to build-up with of designed infrastructure, purchasing approximately customers and This as

as workflows applicable EIP core compatible FX be to library sequencing through kits and program. existing FX a and consumable our As applications will GX reminder, and validated prep all our with informatics and

can in are accuracy oncology, two applications of tissue detection. development application accuracy In generate liquid FX addition for FX and the and HD-seq kits, variant specialized somatic and biopsy. HD-seq is to an kit especially we in kits, sample critical of rare detection rare detection of is Sequencing XR-seq. integrated progressing sequencing prep the QXX and unique in mutation variant the aspect and

the launch, than which to and development quarter XXX continue anticipate read XR-seq reads believe sell vaccines commercial base now sequencing advance for unmet base is discovery are antibody the application XXXX. that greater specialized T areas We target and and of for fourth or we for infectious needs QXX or such targeted quality monitoring is at accuracy a demonstrating XX.XXX%, XX.XXX% pairs the up of in kit XXX therapeutic X,XXX cancers, blood cell of as diagnosing and sequencing for specs for to for accuracy HD-seq on rate scores can base immunology track Extended of of and disease.

this development XXXX. the launch We track the applications in We kit publications to internally are middle quarter continue towards and techniques for year. to on our commercial these the of on anticipate of look these sharing more about of specialized advance fourth being issued forward and

excited and launch, are products about the development Looking GX beyond the pipeline. we our the in

and our that R&D and to for team capabilities age. continue size company We are unmatched a our of believe

disciplines broad distinguish core leverage and integrate competition. is engineering from to ability Singular a the and range of that scientific competency Our the

progress system, protein protein expanding the number in development We the and continuing targets concurrent in to are of PX sequencing RNA make RNA and same detection of demonstrating and on cells. the situ the

We quarter XXXX. of beta are assembling our working now have instruments a of handful expect the beta to in systems and second first

to for planning advance Singular commercial the access are and the customers develop later solutions this offering year, as open PX of and our collaborators program assays launch early with early or application leaders, XXXX. work We in to a thought TAP planned to ability technology

of in the to Her Genomics Nationwide researcher, made updates cancer operational our and Elaine progress, Children's all the recognized focus important improve of diagnosis, and some human a team. to the prognosis Board. to genomics. precision business addition In technologies as has pioneering and added of of Medicine we Elaine serves internationally is disease Hospital. in application understanding Co-Executive been Director genomic Mardis We Mardis medical the our the treatment. at Institute to of

now look academic industry Board. we group NGS next and of community. quarter pipeline. on who their distinguished R&D deliver Additionally, to over With generation the over the experts the company's medical of our call is and turn we our Scientific launched This financial advise We Advisory will details fourth the offerings to I product the results. contributions as and service comprised scientific to of to and Dalen forward go that,

the Drew. the loss product million being company. for XXXX pipeline on the Net to few by share infrastructure for with support to an fourth revenue million, support associated by you, as per $XXX.X quarter short-term brief quarter cash, our fourth $XX.X equivalents QX cash I'll Thank initial year-over-year count orders I'll approximately the of a million. expenses average loss QX quarter of noncash totaled in million A weighted share XX.X future used and growth. XXXX. expected for on in included XX, and the $X.X cash, investments, share, investments XXXX was of public totals in growth, fourth XXXX. or the roadmap, financials, costs operational quarter timing. was followed our of $X.XX to build per including recognition and the XXXX compared total expenses million calculate XXXX. and $XX.X compensation start investment compared on excluding remarks Operating with Ending XXXX. operating comments covering or million headcount per totaled conclude Then launch, by out XXXX share our XXXX, $X.X and $X.XX December million the These to increase restricted of a $X.X in The expense stock-based QX for million quarter GX $X.X to primarily was driven continued net of in R&D fourth update

expect support headcount invest add stock-based up customer R&D. support, and to scale to continue manufacturing, service marketing operating in increase sales, total through innovations compensation of we to XXXX, expenses the as ahead we future and and in including Looking progress

to QX expect We share used XX calculate loss our weighted per count million. average approximately to net be share

early better reception and customers. share transitioning orders, to cycle to early the have Turning we begun plan from and more launch ship to through still is and initial how our orders we mid-year. have visibility our to will orders the we sales positive by begun encouraged orders on have after information funnel are into It in to is take

any the in we we system recognition after be in As of our QX. not subsequent process. do a customary recognized until will on and recognize commence reminder, contingent revenue completion consumables. shipping or result validation a for shipped Revenue initial expect placements could units instruments to upon revenue being periods acceptance This in

shipped schedule. and revenue we as conditions expect revenue more shipment. enable terms and the We information recognition into to timing deliver units on we will term, to shipment recognition better structure to gain will upon Longer associated visibility update shipments our and square speak. I A dedicated assembling infrastructure build running out and operational a is we Diego production and up manufacturing XX,XXX future foot instruments facility instrument our provide additional San on to we brief are support in growth. as plan

XX,XXX in on a are will demand we the our In years. GX space our XXX,XXX well starting executed activities. an additional sciences this support several for to we capitalized additional Pines of Additionally, square needs of in new San the into remain for track to life of square-foot the feet addition move lease in launch XXXX quarter support We the Diego. XXXX. Torrey second headquarters and summary, next new in The capacity hub meet

to achieve our commercial the goals investing We business. scale are and

We the to of large initiatives capture you, front our pipeline and opportunities remarks. has in progress that are making in to product place closing on are back the plan Thank Drew for commercial us. team our confident in market and

I and made proud last Dalen. the over the progress our months. team am you. of Thank few incredibly

launched We the have commercially GX.

at manufacturing we and assembled two in specs initial key world-class with the specs development expertise. and areas. achieved EIP of additional up our production units to We We performance are a system progressed site, continuing commercial stood leading out build dedicated industry have team We sites. targeted demonstrated partner

on have the In first the instruments orders second in taken addition, multiple quarter. to we customers and are ship from track

Lastly, our quarter product and our fourth XXXX. flow specialized to in cells pipeline of is application kits robust, launch with the expected FX

core committed through the to as all of We savings. cost are value GX direct features driving customers for the as system well

will for the With throughput year, this even four level more benchtop GX later so the pricing time. the high sequencer we first by with and the on GX enable

mid is a power, value spans the proposition and high to on market. sequencer flexibility, Industry-leading clear. accuracy throughput that Our speed, cost,

the With GX, are there no tradeoffs.

are major mission to take products and to for our science genomics our accelerate excited advancement a step first bring market on medicine. We and to the of

Q&A, have Joining Dalen me Founder CSO; we for President Head Finance; and Eli Dave and COO. Meeter, Glezer, and of Daly,

Now for questions. let's up open Operator? it

line [Operator the Instructions] from Tycho Our Peterson question first with JPMorgan. of comes

open. Your line is ahead. Please go

just Appreciate all some kit the how important and Curious, around this color improving accuracy. know you can year, path of discussions? talk about later the launch. will early the the QXX. how you to opportunity these accuracy I talk is maybe on that about think you're launching Can HD you you to GX which get and

UMI of this liquid Duli type people or talk there, a really what is that's kind to of Eli kind we specifically, HD-seq detail then accuracy I but probably that unique more And let of HD-seq required about to think, to the And turning techniques, exome for. such when context Tycho, specifically, of designed little accuracy UMI it for what as get that is. biopsy a accuracy absolutely. more drive are that I Meaning RNA-seq is a and the term counting rare is I'll status different specifically about are have accuracy bit really where accuracy for whole-genome. Drew. is profile current in it's Eli HD-seq about. library to that's than think about specifically, matters most And very Yes, you're talking talk sequencing applications prep and variance. of really needed very in

Yes, that's I think a summary. good

art it whole next in hitting across of par the industry that And looking heard whole On the cause the think that's kind than variance continuously to human leading from of presented, call overtime. to published and state -- the that of the type we human kind we then XX%. report big genome on quality the of up that the the of in of and genome last The two our performance as you updates QXX, we've more looking industry on we're basic today. sequencing, our And there. -- improved we've both so entire sequencing the for takes standard level at then, the ability with sequencing sites

raw We terms accuracy. Drew tissue for will or mutations detection continue in that's in intended for variant for of And HD-seq, liquid to do samples, biopsy that mentioned, on as really basic then rare example. the

to are intend of results we XX some -- the around middle now there, out year. hitting QXX the So put we accuracies, on that XX.XXX and this

about kind sense committing get going of R&D mean in orders announced putting appreciate like Okay, all I mode here are that's of quarter. kind giving next the they a GX when you're point? magnitude I this the and Exact, some guess but is and helpful. and of the of know the we're orders it will for get Adaptive really the to it's to or I question at we newer I early customers you've production

that really and can is that Yes, I information backlog Tycho, we few specifics out credible won't market provide provide you we we've until count feel on. predictable, guys for and a gotten probably like the quarters in think, on can

so to and path adoption seeing make only seeing a these the before run, are mean, about In we've crawl adopters for questions I think it's sequencing. early far, taken to quality, barriers good adoption walk committed new companies we're and orders that We've to value sequencing a had of partnering cost I they're they but in general, a terms with sure the savings. the of and to not type also

what operations. think step-wise into expect technology would people new is, would can large sequencing say in a I you So we general clinical

path of matched in in with that provide profile step-wise road. customer just really speed we there. larger to glide the down relationships think flexibility, a a makes cost savings and bigger there the being That it said, vendor terms and think general the do nice approach engagements is I of the the sense GX,

I able breadth, us resolution, can last on just one off. PX, launch? ahead you give On then there details And are of Okay. before the metrics about to any any hop you talk throughput, panel

Yes, over to Eli. turn I'll have that one

Yes.

ballpark sub-micron I of resolution system platform. also will panels say, in And the So and capability variable want a to those the and terms about sequencing the is and also cell And able I or it also applied producing is read And for as of it's the out unique just transcription the categories, just cells, resolution, And then a either proteins use since gene single pathology regions would readout, the example, RNA, combined. just then there. state-of-the-art in in antibodies be have of at sequence specific say designed when lastly, both of panels there in proteins, cells. one that tissue to tissue, for in unique number to of features just RNA PX to we we look two the same for analysis is within each of scale.

XX So we about and use XXX,XXX play format a to so run well per up low . we can

and think can unprecedented the tissue So sections done And XX in today. that's parallel that's those sample wall. same across be with thing I

that some unique the attributes of platform. are those of So

Thank Sachs. of our the Sykes comes from Matt question And with you. next line Goldman

ahead. line Your go Please is open.

on question questions. Maybe for sort type. customer a taking of just my Thanks

groups or you across potential customer diverse pharma, like well some the CRO, gravitating any gotten feel it's of pretty should EIP a whether customer forward? that lot But of pretty of as expect type feedback, base diagnostics, spread it well customer process you types. government, still numbers of is customer and and customer towards those gone fairly is diversified going different and there that type Your additional a demand that is across through kind we

Yes, this Dave Daly. is

You've the hit robust it. very engagement across all We've got a customer segments.

it's the biotech whether research, very academic we're very, clinical, cores, about breadth. start-up, excited whether So fundamental it's

as workflow and you attributes does I opportunity GX customer with four. meet of integration, look the their versatility segments give GX the at speed, those hit GX all to of when specifically that think outlined, really accuracy, the Drew of us or the needs, by the cost,

very be to diverse excited it and So continues and very that. we're about broad

color, Have of Are plan Dalen, still inflation, Great, et kind you you plans? readjust relatively for all of at track you OpEx. original budgeted had had originally maybe that you for for thanks one constraints, supply out or to on on And then in the kind Dave. cetera? subsequent your just to chain the what budget

absolutely. that OpEx, it's an anything definitely how here Specific out, wouldn't in Matt. any to to I'd the OpEx say you've yes, Hi, causes investment Yes. factors in We're that I think inflation Yes, say about phase. or we're XXXX. laid us reset. other that that's increase expecting to of material to

growth. kind we little of to really I efficient. all is think through into through double is XXXX, in in a we've operating But could capital competitive of on phase say, We've investment But headwinds, companies how about market. increase manageable depending XXXX, managing or about the we see expenses that. the of that general, labor we think going bit we've team team more with been But are If like seeing. be just a of market to pace the I got expense that. just support lot are seen some in the job managing expenses higher job

next You million look in at $XXX of philosophy can couple spent history, or the million date. continue our add of course over to years. $XXX investments to here raised, so the We're to going

just then Great. maybe And that. just related to last one,

sort a that little this bit does 'XX, will spend that we see is increase of and type PX, more of kind spend bake of PX or the on in year that a on spend Just of some OpEx plan?

part program now, beta No, We're access bringing we'll the units. technology we're right phase actively you be working on moving here in up year. this say, of can development. into, here, that last

OpEx as PX includes spend So well. that

John Thank UBS. our comes line you. question from the And Sourbeer next of with

is open. ahead. line go Your Please

Maybe Thanks. improvements? or been on various impressions converted you feedback that Appreciate focus to on there any and that you maybe early feedback maybe provide could all the just has additional any customers, for there. there yet customers the orders, or provided color access the haven't

helpful customers. one much really buying is also or a institution. if both of an versus Yes, from I'd that in core looking kind system number type learning but It's of a company perspective, academic or say the at EIP cycle. public some about you're been holistically different a learning part a about of the And lab has of ways, the understanding, private

No differences in most point of and cycles hopeful So at not happens we relationship. in point we're buying budgeting of that. at customer-vendor if in convert We're some to in there's color customers learning that these time. that terms this can and way the EIPs definitely through all additional these

Got additional color. company you this has just And to it. partnerships maybe or fill. for Thanks there details more for of announced addition that focus the of few areas the year, the Any week. think any several begin

color think is names don't on there the involved. I more

I of is maybe, that the on as the sure higher practical focused we adoption possible. very seamless think that is the making are that takeaway sequencing as

of team get they very moments plan there So any that compatibility essentially that time there informatics this using these platform solutions are through any, focused hurdles new activities don't nuances have system drops and already spend they that's partnerships in the differences sequencing third data on And when they've figured the prep out running are customer the in. they're that the a that set partnerships, labs are or systems a are been and adopters. to of aha sure to holistically or protocols, understanding that of really the different confusion whether is we're them we end used of that shipping library make the that's reaching back when quarter all for to party kind before, library on intended are prep, front with the the and we and

I is seamless we of it's the sequencer the really would adoption do kit using. positive how So existing that in all that of to have make same say kind a accustomed sure direction experiences and already users and they're with

of Ryskin Thank of America. And from comes the next Bank you. our with question line Michael

is line go Your Please ahead. open.

for Good Mike. Peter afternoon, is this on

that more intact? different TAP here. just you can still had I previously definitely there in if on we I'm I of timeline any second the the from PX, wondering anything share. on there's appreciate the you can A, detail there days is is then, it's half you on plan? So expect believe still launch give I think B, XXXX. could you that new commented GX. the it touched the And guess, early

Yes, absolutely.

the of then I'll a second of let program. year. the little still more TAP of kind about bit have cover first and So half talk part the schedule I for on PX do Eli, next it guess, I'll We

again that are and so trivial launching product, is speak. our a We pursuit, not to first

sure our platform is are this be we successful, organization on that aware on of and the success So no GX making that. first needs very make to focused mistake the

according that we with go plan. group We to PX things a and have push are trying we the GX, sure assuming to are successful make continuing to the forward

our are on system, be timeline. right As that with investment they priority. and it stay very that should But now, largely is on we continue of able we do second to to which success first the timeline will the be has transparent the the system

I'll program. a to turn access In little he the in mind terms about talk it more technology over to of has there? bit what Eli

bit the than It be targeting. for to thanks really sequencers clear program different little the the the access of customers' very in that GX. the we're early operation we're going our a for validate Yes, program trying In hands. applications is that In question. just we're to

there as tissue, single earlier, with some area we is bit do to the customers range of possibilities little thought out, this us I reading to promising help For work mentioned the program, most through in the there. proteins, is PX, cell direct sequencing, panels, the in that access hope guide such large directions potentially and a RNA broad analysis, technology leaders a

program. And access technology that's the of so part

custom on to specific work further develop our then And with maybe guide applications, needs. that will development closely people commercialization. panel We head those those we will as towards

All roll I are thanks. major impacting out. an then, there announcement of thinking How there you kind to expected right. platform couple Great, how of to is by within your and anything months you. another a given here? competitor in potential Thank then launch? the with you have about this January specifically is pending evolved And past speak can customers is discussions know

Yes, hey, Dave. Peter, this is

think continues real. I As accelerating. the of all the customer is across segments and the I strong. it's of various again, be of very engagements, the in been funnel very demonstrating proposition to has The GX, engagement mentioned robust, as itself And very, previously, fact number we're the value

is laboratories to that that laboratory program insight of the systems into access parties that that run just a third thing think their you and provided mentioned think get haven't when early for samples send these one in processing. I given us -- shipping we I helpful is, be you actually them having laboratory, lot don't their has

to customers the play. So how actually target specifically can plug we GX these talk can and about

as partnerships locations. likewise various partnerships, prospect about utilization customer with the of the Drew I indicated with, think back-end analytics we at the can these upfront GX secondly library real-world talk

capabilities engagement. really So actual accelerated of we're ability the again system, talking customer about to that and has the do not conceptual. We're those talking

the funnel. So but really in of number feeling the the only that good number the acceleration about not

space. on I'll guess to going add I competition. There's competition this the just be in

on largely making is, with meet what's we put I very sure that making and we've are within and out sure that or that has and exceed we're to think customers. to focused that that what we're aggressive listening our the control engaging do specs

mid-throughput the unique right simple is and output from what works to I now thing and one at, market where here by to four per the we're $XX of the a we're if pricing GX you GX expanding the throughput and then it's the now or digit, mentioning, to both $XX, high those of the in system power up between basis, high-single-digit, mid-single of the market maybe really and kind up probably speed giga with throughput ranging about is pricing that look think mean spans a that. by kind base is how is way, and worth that in on how the of essentially of really profile the It on and a high the mid-throughput I is higher systems. and two gap kind kind $XX talking kind XX. so the What of about teens

unique So think, provide will proposition, mean of for will really gap, be that very that trade-offs, it's say the some this offering system, of some speed it no the differentiated that's, that a a we offering and flexibility the a we be very fact unique quite the we the of really unique of time. system system, I value when spans mean

from Thank our the next comes you. of Dan And line question Brennan with Cowen.

Your line is Please go open. ahead.

terms taking cells, same the early or Thanks, ability in all the to questions. four customers is the to Maybe of they, pretty gig, up wanting per flow far, get on going first and or cells one and the in would the the that's flow like way cell guys, differentiator one users and GX, the flexibility like, the one the pricing of beta the run, flow for be, a like driver so viewpoint are funnel, for of a big your terms customer? cell that how two to amongst often flow be big

of come for allows be academic think all PIs dam or batch doing them I a where sequencing. about is feet, core serving be lab more type that customer. big efficient to week. in of thinking cells the subset of their those faster turnaround I fleets multiple another think are have operate of in customers a And very requirements. this their customers probably can certain are that their type those really fashion bridged to different are are of set flow the you terms going per are customers for they're those, an system parallel it's profile customers certainly types in that There of runs running flexibility of example, lab Yes, or really samples depends using that where to next a minimal profiles just And or in, driver and cater that four something the throughput lowers cost. types going are sample has of really, is it if they're and this to the There on

cell the ready to up load can systems You a day. next go run single flow the

to to don't all You have gig cell. run week-to-batch XXX flow wait

it customer on question the needs So best answered, can be those well. and it's it both if of I very the really, think depends

Drew. Thanks, Great.

we kind I things been that key you've like smaller have fixed as were right that has It that to out the learnings so been sounds certain has there things of the you've had assume, terms of like far, been In been, see. are a of beta learnings will, like of you through things GX where now? but won't bunch well you've kind tweak if able going there any of things does this such gone there box,

been their versus I the government ton purchase about. for and and of a were own of on terms people There's side, very just it's is versus validation. the And way been learnings I different large the commercial about company definitely guess look There's think learnings. there -- a again, of are lot a private also small Dave in like, talking learnings a entity. what private in company

In know much to feel terms want that of here turn candid. Eli. I go one the actual into technical detail don't how probably be you free but over learning, to I'll to

work with real for it's valuable real would I to library us say been customers, methods. samples, preparation real

libraries want the way in suitable small so you process things the insert example, in adjusting we one make So maybe and one are up we give their that. it case, I to to particularly some data

also and overlayered all it's been parallel done that, own in to sort meet -- just and see sequencing important that applications fundamental nothing sort So prepared able this output be I systems. on and various would internal progress we all the year commercial our types of during in of quality things to but rollout the those And the be of as of as just to happening EIP program. that's we've sort the deeply that,

for Great, that. thanks

obviously comment like to look backlog this placements the comment any expected really have you street the seeing I look on in on talked at look mean, we the what In terms if translate of at not full as just year? you where can but but, final at conversion, that qualitatively, is, you all you're funnel might thoughts the is, any how we going as directly, the now Dave, ahead obviously, year I like feel about XX think we're with about. obviously good we'd funnel numbers street -- we giving the the not funnel, around funnel for

XX the that, any back-end and in it's bringing filling that an chime anyone this provided about new QX of funnel, is change here. units we and technology as a perspective I'll opportunity a product to guidance manufacturing there, at new that in just revenue day, in and layup to commercial public by customer company, achieve can there We're are aware formal challenge, loaded There but out model, to and consensus on on as we're Dan, right. conversations yes, units is would reminder, Dalen, first yes, But, any the take right. our market the From achievable all, we're means. units it's definitely XX absolutely out in and ops QX. well. no going sales every time, I for We're the it's perspective, say learning units building is this. haven't a but a

So that's have little a of anything and of an I'd if bit you don't say that? Dave, overview I know else

bit lab on you is touched Dan, to also the two more a little to academic account, is, more variety have three you of startup take think look can Yes, cycle, I a a or are at I you think, sales into month six cycle, you there when is this nine know, to lab a quickly. bit move months core biotech a in cycle, clinical funnel

sales to lot a that and now So while have is to the to the you've then numbers got cycles Dalen you gave.. in bake of there a various full robustness, funnel get

Great. the product it to there? that be is And final just you're interested yes, maybe on Is going then Got see the who four of customer it. who one, -- by four, marketing just kind to? to target

four consistently think power been kind by of about have we that I SX. Yes, since it the we something was four talking

throughput customers, into always there we allowing with as that that people an we continue opportunity a high scaling sequencer. strong something talking feel So were to is this and found been a is super alternative and

a scale, seeking $X a system. to, It's down lot is of deal. million and comes big which that's a cost. usually lot it tag, If is into about people why they high a step and are price have throughput usually you a there big of a volume lower they CapEx think But

lot we more. and customers we're to grid So the the people and to essentially to provide a SX total it's and the are and point thought value just a alternative sure have into SPs, a customers you point at of a you a of say capture process on first, mid-throughput are but with value great, be the better proposition need and able and with those certain that going four I'm those the like, cost a cell, of it's having similar that a those could high the by stepping a something trying flow and system, LDTs lab, grid is a flexible or know a Again, that running that want cost really attractive to lot to have about make think those you times, be central throughput talked clinical point, to but attractive is would clear market. of a SXs, if And faster, we a SX, system. customers be more going lot SXs, at certain just we that that that instrument that's large that's and SP them price more cost an when four percentage it's labs, running it labs, customers And capacity an research a environment proposition. the you and four customers

that throughput, have and customers. allows those to by attractive directly your you grid, a the for at extend alternative and look the by doing mid-throughput, into we If really four, standpoint throughput simple. very really higher it cost grid it's throughput So your four provide us from an low

And I what four point, is, that mind at think, just independent articulated keep additional higher GX you're them. by higher is volumes in looking and throughputs, the complement Dan, to you other harmonizing one four taking four and

running to types be to time relatively needs run quickly, a the if do not you more now the experiment processed have have greater to only same have you something your now you've get ability something experiments system. large you So at have you run got opportunity the to but or of and simultaneously that volume, access to

Then that's setting. stepped. more that a bit a something workflow volume different really in you're higher So think a with scenario I provides getting

reload for you you a you can to systems The most four by You flow it in of that got it. high then you get to gives loaded, lot four don't before wait finish today. throughput work flexibility

question does this today's a answer And you does Ladies gentlemen, may great participating for conclude also you. and now conclude call. Everyone, Thank this day. conference and have today's session. and Thank you disconnect.